3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Gastrointestinal Stromal Tumors
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia
2
Burkitt Lymphoma
2
Squamous Cell Carcinoma of Head and Neck
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Melanoma
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia, Biphenotypic, Acute
1
Hypereosinophilic Syndrome
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Digestive System Neoplasms
1
Congenital Bone Marrow Failure Syndromes
1
Blast Crisis
1
Interventions
Magnetic Resonance Spectroscopy
8
X-Rays
6
Specimen Handling
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
5
Biopsy
4
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
lutetium Lu 177 dotatate
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
LY3023414
2
pembrolizumab
1
neratinib
1
cemiplimab
1
brigatinib
1
Watchful Waiting
1
Vincristine
1
Vemurafenib
1
Temozolomide
1
Radiotherapy, Conformal
1
Radiotherapy
1
Radiation
1
Platinum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Ependymoma
×
Imatinib Mesylate
×
90 days
×
Clear all
No trials found.